#BEGIN_DRUGCARD DB00847

# AHFS_Codes:
Not Available

# ATC_Codes:
A16AA04

# Absorption:
Cystagon® reaches its maximum plasma concentration in about 1.4 hours.

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Becaptan
Cystagon
Cystaran
Cystavision
Lambraten
Lambratene
Mecramine
Mercamin
Merkamin
Procysbi
Riacon

# CAS_Registry_Number:
60-23-1

# ChEBI_ID:
17141

# Chemical_Formula:
C2H7NS

# Chemical_IUPAC_Name:
2-aminoethane-1-thiol

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Cysteamine is a radiation-protective agent that oxidizes in air to form cystamine. It can be given intravenously or orally to treat radiation sickness. The bitartrate and hydrochloride salt forms are indicated for the treatment of cystinosis [PubChem]. Cysteamine is marketed under several brand names such as Cystaran™ and Cystagon®.

# Dosage_Forms:
Capsule	Oral
Capsule	Oral
Solution / drops	Ophthalmic

# Drug_Category:
Nephropathic cystinosis therapy
Ophthalmics
Radiation-Protective Agents

# Drug_Interactions:
Not Available

# Drug_Reference:
11458646	Lukashin BP, Grebeniuk AN: [Comparative study of the radiation-protective effectiveness of low doses of cysteamine, heparin, and naphtizine in experiments on mice] Radiats Biol Radioecol. 2001 May-Jun;41(3):310-2.

# Drug_Type:
Approved
Investigational
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
0.1

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Cysteamine

# HET_ID:
Not Available

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C2H7NS/c3-1-2-4/h4H,1-3H2

# InChI_Key:
InChIKey=UFULAYFCSOUIOV-UHFFFAOYSA-N

# Indication:
Given intravenously or orally to treat radiation sickness. The bitartrate salt (Cystagon®) has been used for the oral treatment of nephropathic cystinosis and cystinurea. The hydrochloride salt (Cystaran™) is indicated for the treatment of corneal cystine crystal accumulation in cystinosis patients.

# KEGG_Compound_ID:
C01678

# KEGG_Drug_ID:
D03634

# LIMS_Drug_ID:
847

# Mechanism_Of_Action:
The free thiol cysteamine depletes cystinotic leukocytes and other cells of cystine, whose accumulation is considered the cause of organ damage in cystinosis. Cysteamine cleaves the disulfide bond with cystine to produce molecules that can escape the metabolic defect in cystinosis and cystinuria.

# Melting_Point:
98 °C

# Molecular_Weight_Avg:
77.149

# Molecular_Weight_Mono:
77.029919919

# Organisms_Affected:
Humans and other mammals

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
PA449171

# Pharmacology:
People born without the ability to metabolize the amino acid cystine suffer from cystinosis, a rare inherited disorder characterized by the deposition and accumulation of cystine crystals throughout the body. These crystals cause considerable damage, particularly in the kidney and eye. Kidney failure can occur by the age of 10 in untreated patients. Cysteamine prevents the accumulation of cystine crystals and is prescribed to prevent further kidney and eye damage. Cysteamine helps to convert cystine into less harmful chemical forms that can be removed from cells.

# Predicted_LogP_Hydrophobicity:
0.01

# Predicted_LogS:
-0.52

# Predicted_Water_Solubility:
2.35e+01 g/l

# Primary_Accession_No:
DB00847

# Protein_Binding:
Cysteamine has a plasma protein binding of 52% and is mostly bound to albumin.

# PubChem_Compound_ID:
6058

# PubChem_Substance_ID:
46507730

# RxList_Link:
http://www.rxlist.com/cystagon-drug.htm

# Salts:
CYSTEAMINE BITARTRATE
CYSTEAMINE HYDROCHLORIDE

# Secondary_Accession_No:
APRD00896

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
NCCS

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
(2-Mercaptoethyl)amine
2-Amino-1-ethanethiol
2-Aminoethanethiol
2-Aminoethyl mercaptan
2-Mercaptoethanamine
Aminoethyl mercaptan
Cisteamina
Cysteamide
Cysteamin
Cysteinamine
Decarboxycysteine
Ethanethiolamine
MEA
Mercamine
Mercaptamin
Thioethanolamine
beta-Aminoethanethiol
beta-MEA
beta-Mercaptoethylamine

# Synthesis_Reference:
Not Available

# Toxicity:
Symptoms of overdose may include convulsions (seizures), increased thirst and unusual tiredness or weakness.

# Update_Date:
2013-05-20 22:10:58 -0600

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Cysteamine

# pKa_Isoelectric_Point:
Not Available

# Phase_1_Metabolizing_Enzyme_1_Gene_Name:
MPO

# Phase_1_Metabolizing_Enzyme_1_ID:
1757

# Phase_1_Metabolizing_Enzyme_1_Name:
Myeloperoxidase

# Phase_1_Metabolizing_Enzyme_1_Protein_Sequence:
>Myeloperoxidase precursor
MGVPFFSSLRCMVDLGPCWAGGLTAEMKLLLALAGLLAILATPQPSEGAAPAVLGEVDTS
LVLSSMEEAKQLVDKAYKERRESIKQRLRSGSASPMELLSYFKQPVAATRTAVRAADYLH
VALDLLERKLRSLWRRPFNVTDVLTPAQLNVLSKSSGCAYQDVGVTCPEQDKYRTITGMC
NNRRSPTLGASNRAFVRWLPAEYEDGFSLPYGWTPGVKRNGFPVALARAVSNEIVRFPTD
QLTPDQERSLMFMQWGQLLDHDLDFTPEPAARASFVTGVNCETSCVQQPPCFPLKIPPND
PRIKNQADCIPFFRSCPACPGSNITIRNQINALTSFVDASMVYGSEEPLARNLRNMSNQL
GLLAVNQRFQDNGRALLPFDNLHDDPCLLTNRSARIPCFLAGDTRSSEMPELTSMHTLLL
REHNRLATELKSLNPRWDGERLYQEARKIVGAMVQIITYRDYLPLVLGPTAMRKYLPTYR
SYNDSVDPRIANVFTNAFRYGHTLIQPFMFRLDNRYQPMEPNPRVPLSRVFFASWRVVLE
GGIDPILRGLMATPAKLNRQNQIAVDEIRERLFEQVMRIGLDLPALNMQRSRDHGLPGYN
AWRRFCGLPQPETVGQLGTVLRNLKLARKLMEQYGTPNNIDIWMGGVSEPLKRKGRVGPL
LACIIGTQFRKLRDGDRFWWENEGVFSMQQRQALAQISLPRIICDNTGITTVSKNNIFMS
NSYPRDFVNCSTLPALNLASWREAS

# Phase_1_Metabolizing_Enzyme_1_SwissProt_ID:
P05164

# Drug_Target_1_Cellular_Location:
Not Available

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
21147534	Omran Z, Kay G, Di Salvo A, Knott RM, Cairns D: PEGylated derivatives of cystamine as enhanced treatments for nephropathic cystinosis. Bioorg Med Chem Lett. 2011 Jan 1;21(1):45-7. Epub 2010 Nov 21.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
Not Available

# Drug_Target_1_GenBank_ID_Protein:
Not Available

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
Not Available

# Drug_Target_1_Gene_Sequence:
Not Available

# Drug_Target_1_General_Function:
Not Available

# Drug_Target_1_General_References:
Not Available

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
7217

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
Not Available

# Drug_Target_1_Name:
cystine

# Drug_Target_1_Number_of_Residues:
0

# Drug_Target_1_PDB_ID:
Not Available

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
Not Available

# Drug_Target_1_Protein_Sequence:
Not Available

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
Not Available

# Drug_Target_1_Specific_Function:
Not Available

# Drug_Target_1_SwissProt_ID:
Not Available

# Drug_Target_1_SwissProt_Name:
Not Available

# Drug_Target_1_Synonyms:
Not Available

# Drug_Target_1_Theoretical_pI:
Not Available

# Drug_Target_1_Transmembrane_Regions:
Not Available

# Drug_Target_2_Cellular_Location:
Secreted protein

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
11752352	Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.
2653642	Ahren B, Bottcher G, Ekman R, Sundler F: Cysteamine and the endocrine pancreas: immunocytochemical, immunochemical, and functional aspects. Cell Tissue Res. 1989 Apr;256(1):159-66.
2901134	McIntosh CH, Bakich V, Bokenfohr K, DiScala-Guenot D, Kwok YN, Brown JC: Cysteamine-induced reduction in gastrointestinal somatostatin: evidence for a region-specific loss in immunoreactivity. Regul Pept. 1988 Jun;21(3-4):205-18.
4080089	Terry LC, Craig R: Cysteamine effects on monoamines, dopamine-beta-hydroxylase and the hypothalamic-pituitary axis. Neuroendocrinology. 1985 Dec;41(6):467-75.
6142843	McIntosh C, Bakich V, Trotter T, Kwok YN, Nishimura E, Pederson R, Brown J: Effect of cysteamine on secretion of gastrin and somatostatin from the rat stomach. Gastroenterology. 1984 May;86(5 Pt 1):834-8.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
SST

# Drug_Target_2_GenBank_ID_Gene:
J00306

# Drug_Target_2_GenBank_ID_Protein:
338288

# Drug_Target_2_GeneCard_ID:
SST

# Drug_Target_2_Gene_Name:
SST

# Drug_Target_2_Gene_Sequence:
>351 bp
ATGCTGTCCTGCCGCCTCCAGTGCGCGCTGGCTGCGCTGTCCATCGTCCTGGCCCTGGGC
TGTGTCACCGGCGCTCCCTCGGACCCCAGACTCCGTCAGTTTCTGCAGAAGTCCCTGGCT
GCTGCCGCGGGGAAGCAGGAACTGGCCAAGTACTTCTTGGCAGAGCTGCTGTCTGAACCC
AACCAGACGGAGAATGATGCCCTGGAACCTGAAGATCTGTCCCAGGCTGCTGAGCAGGAT
GAAATGAGGCTTGAGCTGCAGAGATCTGCTAACTCAAACCCGGCTATGGCACCCCGAGAA
CGCAAAGCTGGCTGCAAGAATTTCTTCTGGAAGACTTTCACATCCTGTTAG

# Drug_Target_2_General_Function:
Involved in hormone activity

# Drug_Target_2_General_References:
6126875	Shen LP, Pictet RL, Rutter WJ: Human somatostatin I: sequence of the cDNA. Proc Natl Acad Sci U S A. 1982 Aug;79(15):4575-9.
6142531	Shen LP, Rutter WJ: Sequence of the human somatostatin I gene. Science. 1984 Apr 13;224(4645):168-71.

# Drug_Target_2_HGNC_ID:
HGNC:11329

# Drug_Target_2_HPRD_ID:
08920

# Drug_Target_2_ID:
1736

# Drug_Target_2_Locus:
3q28

# Drug_Target_2_Molecular_Weight:
12736

# Drug_Target_2_Name:
Somatostatin

# Drug_Target_2_Number_of_Residues:
116

# Drug_Target_2_PDB_ID:
Not Available

# Drug_Target_2_Pathway:
Cimetidine Pathway	SMP00232
Esomeprazole Pathway	SMP00225
Famotidine Pathway	SMP00231
Lansoprazole Pathway	SMP00227
Nizatidine Pathway	SMP00233
Omeprazole Pathway	SMP00226
Pantoprazole Pathway	SMP00228
Pirenzepine Pathway	SMP00246
Rabeprazole Pathway	SMP00229
Ranitidine Pathway	SMP00230

# Drug_Target_2_Pfam_Domain_Function:
PF03002	Somatostatin

# Drug_Target_2_Protein_Sequence:
>Somatostatin precursor
MLSCRLQCALAALSIVLALGCVTGAPSDPRLRQFLQKSLAAAAGKQELAKYFLAELLSEP
NQTENDALEPEDLSQAAEQDEMRLELQRSANSNPAMAPRERKAGCKNFFWKTFTSC

# Drug_Target_2_Reaction:
Not Available

# Drug_Target_2_Signals:
1-24

# Drug_Target_2_Specific_Function:
Somatostatin inhibits the release of somatotropin

# Drug_Target_2_SwissProt_ID:
P61278

# Drug_Target_2_SwissProt_Name:
SMS_HUMAN

# Drug_Target_2_Synonyms:
Growth hormone release-inhibiting factor
Somatostatin precursor

# Drug_Target_2_Theoretical_pI:
5.18

# Drug_Target_2_Transmembrane_Regions:
None

# Drug_Target_3_Cellular_Location:
Membrane

# Drug_Target_3_Chromosome_Location:
Not Available

# Drug_Target_3_Drug_References:
1314592	Li W, Hexum TD: Cysteamine selectively enhances neuropeptide Y2 receptor binding activity. Biochem Biophys Res Commun. 1992 Apr 15;184(1):380-6.

# Drug_Target_3_Essentiality:
Non-Essential

# Drug_Target_3_GenAtlas_ID:
NPY2R

# Drug_Target_3_GenBank_ID_Gene:
U36269

# Drug_Target_3_GenBank_ID_Protein:
Not Available

# Drug_Target_3_GeneCard_ID:
Not Available

# Drug_Target_3_Gene_Name:
NPY2R

# Drug_Target_3_Gene_Sequence:
>1146 bp
ATGGGTCCAATAGGTGCAGAGGCTGATGAGAACCAGACAGTGGAAGAAATGAAGGTGGAA
CAATACGGGCCACAAACAACTCCTAGAGGTGAACTGGTCCCTGACCCTGAGCCAGAGCTT
ATAGATAGTACCAAGCTGATTGAGGTACAAGTTGTTCTCATATTGGCCTACTGCTCCATC
ATCTTGCTTGGGGTAATTGGCAACTCCTTGGTGATCCATGTGGTGATCAAATTCAAGAGC
ATGCGCACAGTAACCAACTTTTTCATTGCCAATCTGGCTGTGGCAGATCTTTTGGTGAAC
ACTCTGTGTCTACCGTTCACTCTTACCTATACCTTAATGGGGGAGTGGAAAATGGGTCCT
GTCCTGTGCCACCTGGTGCCCTATGCCCAGGGCCTGGCAGTACAAGTATCCACAATCACC
TTGACAGTAATTGCCCTGGACCGGCACAGGTGCATCGTCTACCACCTAGAGAGCAAGATC
TCCAAGCGAATCAGCTTCCTGATTATTGGCTTGGCCTGGGGCATCAGTGCCCTGCTGGCA
AGTCCCCTGGCCATCTTCCGGGAGTATTCGCTGATTGAGATCATCCCGGACTTTGAGATT
GTGGCCTGTACTGAAAAGTGGCCTGGCGAGGAGAAGAGCATCTATGGCACTGTCTATAGT
CTTTCTTCCTTGTTGATCTTGTATGTTTTGCCTCTGGGCATTATATCATTTTCCTACACT
CGCATTTGGAGTAAATTGAAGAACCATGTCAGTCCTGGAGCTGCAAATGACCACTACCAT
CAGCGAAGGCAAAAAACCACCAAAATGCTGGTGTGTGTGGTGGTGGTGTTTGCGGTCAGC
TGGCTGCCTCTCCATGCCTTCCAGCTTGCCGTTGACATTGACAGCCAGGTCCTGGACCTG
AAGGAGTACAAACTCATCTTCACAGTGTTCCACATCATCGCCATGTGCTCCACTTTTGCC
AATCCCCTTCTCTATGGCTGGATGAACAGCAACTACAGAAAGGCTTTCCTCTCGGCCTTC
CGCTGTGAGCAGCGGTTGGATGCCATTCACTCTGAGGTGTCCGTGACATTCAAGGCTAAA
AAGAACCTGGAGGTCAGAAAGAACAGTGGCCCCAATGACTCTTTCACAGAGGCTACCAAT
GTCTAA

# Drug_Target_3_General_Function:
Involved in rhodopsin-like receptor activity

# Drug_Target_3_General_References:
7559383	Rose PM, Fernandes P, Lynch JS, Frazier ST, Fisher SM, Kodukula K, Kienzle B, Seethala R: Cloning and functional expression of a cDNA encoding a human type 2 neuropeptide Y receptor. J Biol Chem. 1995 Sep 29;270(39):22661-4.
7592910	Gerald C, Walker MW, Vaysse PJ, He C, Branchek TA, Weinshank RL: Expression cloning and pharmacological characterization of a human hippocampal neuropeptide Y/peptide YY Y2 receptor subtype. J Biol Chem. 1995 Nov 10;270(45):26758-61.
8632753	Gehlert DR, Beavers LS, Johnson D, Gackenheimer SL, Schober DA, Gadski RA: Expression cloning of a human brain neuropeptide Y Y2 receptor. Mol Pharmacol. 1996 Feb;49(2):224-8.
8643460	Yan H, Yang J, Marasco J, Yamaguchi K, Brenner S, Collins F, Karbon W: Cloning and functional expression of cDNAs encoding human and rat pancreatic polypeptide receptors. Proc Natl Acad Sci U S A. 1996 May 14;93(10):4661-5.
8975716	Ammar DA, Eadie DM, Wong DJ, Ma YY, Kolakowski LF Jr, Yang-Feng TL, Thompson DA: Characterization of the human type 2 neuropeptide Y receptor gene (NPY2R) and localization to the chromosome 4q region containing the type 1 neuropeptide Y receptor gene. Genomics. 1996 Dec 15;38(3):392-8.

# Drug_Target_3_HGNC_ID:
HGNC:7957

# Drug_Target_3_HPRD_ID:
Not Available

# Drug_Target_3_ID:
4186

# Drug_Target_3_Locus:
4q31

# Drug_Target_3_Molecular_Weight:
42732

# Drug_Target_3_Name:
Neuropeptide Y receptor type 2

# Drug_Target_3_Number_of_Residues:
381

# Drug_Target_3_PDB_ID:
Not Available

# Drug_Target_3_Pathway:
Not Available

# Drug_Target_3_Pfam_Domain_Function:
PF00001	7tm_1

# Drug_Target_3_Protein_Sequence:
>Neuropeptide Y receptor type 2
MGPIGAEADENQTVEEMKVEQYGPQTTPRGELVPDPEPELIDSTKLIEVQVVLILAYCSI
ILLGVIGNSLVIHVVIKFKSMRTVTNFFIANLAVADLLVNTLCLPFTLTYTLMGEWKMGP
VLCHLVPYAQGLAVQVSTITLTVIALDRHRCIVYHLESKISKRISFLIIGLAWGISALLA
SPLAIFREYSLIEIIPDFEIVACTEKWPGEEKSIYGTVYSLSSLLILYVLPLGIISFSYT
RIWSKLKNHVSPGAANDHYHQRRQKTTKMLVCVVVVFAVSWLPLHAFQLAVDIDSQVLDL
KEYKLIFTVFHIIAMCSTFANPLLYGWMNSNYRKAFLSAFRCEQRLDAIHSEVSVTFKAK
KNLEVRKNSGPNDSFTEATNV

# Drug_Target_3_Reaction:
Not Available

# Drug_Target_3_Signals:
None

# Drug_Target_3_Specific_Function:
Receptor for neuropeptide Y and peptide YY. The rank order of affinity of this receptor for pancreatic polypeptides is PYY > NPY > PYY (3-36) > NPY (2-36) > [Ile-31, Gln-34] PP > [Leu- 31, Pro-34] NPY > PP, [Pro-34] PYY and NPY free acid

# Drug_Target_3_SwissProt_ID:
P49146

# Drug_Target_3_SwissProt_Name:
NPY2R_HUMAN

# Drug_Target_3_Synonyms:
NPY-Y2 receptor
NPY2-R

# Drug_Target_3_Theoretical_pI:
7.26

# Drug_Target_3_Transmembrane_Regions:
50-72
83-104
125-146
167-187
215-240
269-291
305-328

#END_DRUGCARD DB00847
